European CML Blast Crisis Register — BlastCrisis  

Chronic Myeloid Leukemia in Myeloid Blast Crisis Clinical Trial

Official title: European CML Blast Crisis Register

Status Recruiting

Clinical Trial Summary

Multicentric prospective and retrospective register collecting patient with CML blast crisis diagnosed in Germany and Europe

Clinical Trial Description

Since the advent of treatment with tyrosine kinase inhibitors (TKI), the incidence of blast crises has significantly decreased. Nevertheless, about 5% of patients diagnosed with chronic myeloid leukemia (CML) will evolve into a blast phase at some point during the course of their disease. Furthermore, despite the advances made in CML treatment, outcome of patients with blast crises are still dismal. Due to the rarity of this condition clinical trials are challenging, and collaboration between researchers both at national and international level is needed to collect a meaningful number of data. ;

Related Conditions & MeSH terms

• Blast Crisis
• Chronic Myeloid Leukemia in Myeloid Blast Crisis
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive

• NCT number: NCT03869502
• Study type: Observational [Patient Registry]
• Source: University of Jena
• Contact: Annamaria Brioli, PhD MD
• Phone: +49 36419324576
• Email: blastcrisis@med.uni-jena.de
• Status: Recruiting
• Start date: October 25, 2018
• Completion date: June 30, 2024